Clinical compliance with an oral uracil/tegafur (UFT) plus leucovorin (LV) regimen as adjuvant chemotherapy in Japanese colorectal cancer patients
Clinical compliance with an oral uracil/tegafur (UFT) plus leucovorin (LV) regimen as adjuvant chemotherapy in Japanese colorectal cancer patients
复制标题
DOI：
10.1007/s10147-009-0888-1
复制
发表时间：
2009-10-01
影响因子：
3.3
通讯作者：
Hirata, Koichi
中科院分区：
文献类型：
--
作者：
Meguro, Makoto;Furuhata, Tomohisa;Hirata, Koichi
口服尿嘧啶/替加氟（UFT）联合甲酰四氢叶酸（LV）被广泛接受为II期和III期结直肠癌的辅助化疗。然而，迄今为止，日本患者对该方案的临床依从性尚不清楚。2005年1月至2007年6月期间，共有40例日本门诊患者在结直肠癌手术后接受口服UFT联合LV作为辅助化疗。UFT胶囊（300-500 mg/人/天）和LV片剂（75 mg/人/天，与每次UFT给药一起给药）给药28天，然后停药7天，每35天重复一次该周期，持续6个月或直至复发。根据依从性将患者分为以下三组：完成组（n = 21）、改良组（n = 12）和中止组（n = 7）。完成组的平均剂量（平均值+/- SD）为267 +/- 35 mg/m2，改良组为276 +/- 50 mg/m2，停药组为288 +/- 22 mg/m2。中止组的UFT剂量倾向于高于完成组（P = 0.12）。最常见的非血液学毒性症状是食欲不振（45%）和疲劳（45%）。口服UFT加LV方案毒性低，便于门诊患者使用。初始UFT剂量似乎与口服UFT + LV方案中的毒性发生相关。
The combination of oral uracil/tegafur (UFT) plus leucovorin (LV) is widely accepted as adjuvant chemotherapy for stages II and III of colorectal cancer. However, the clinical compliance of Japanese patients with this regimen has not been clearly elucidated to date.A total of 40 Japanese outpatients were treated with oral UFT plus LV as adjuvant chemotherapy following colorectal cancer surgery between January 2005 and June 2007. UFT capsules (300-500 mg/body per day) and LV tablets (75 mg/body per day, administered with each dose of UFT) were to be taken for 28 days, followed by 7 days of rest, with this cycle repeated every 35 days for 6 months or until recurrence. The patients were classified into the following three groups based on compliance: the completed group (n = 21), the modified group (n = 12), and the discontinued group (n = 7).The UFT doses (mean +/- SD) were 267 +/- 35 mg/m(2) in the completed group, 276 +/- 50 mg/m(2) in the modified group, and 288 +/- 22 mg/m(2) in the discontinued group. The UFT dose in the discontinued group tended to be higher than that in the completed group (P = 0.12). The most frequent symptoms of nonhematologic toxicity were appetite loss (45%) and fatigue (45%). There were no hematologic or nonhematologic toxicities of grade 3 or 4.The regimen of oral UFT plus LV produced only low-grade toxicity and was convenient for outpatients. It appears that the initial UFT dose might be associated with the development of toxicity in the oral UFT plus LV regimen.